Ultragenyx (RARE) Stock Could Stay Fully Priced On Setrusumab Regulatory Talks
Ultragenyx Pharmaceutical stock has retreated sharply over the past few years, yet current valuation checks suggest the shares are not a clear bargain. Recent price weakness, including a fall over the past month, now meets a mixed verdict from the broader valuation framework.
- Ultragenyx Pharmaceutical has declined 70.8% over the past 5 years, which may lead some investors to question whether sentiment has become too pessimistic or if the earlier pricing was simply too optimistic.
- Progress with setrusumab in osteogenesis imperfecta alongside partner Mereo BioPharma can support expectations for future revenue, while regulatory outcomes and execution on this program may also limit how much value investors are willing to ascribe today.
- With a value score of 4 out of 6, Ultragenyx Pharmaceutical presents a mixed picture rather than a clear bargain or clear overvaluation.
The stock's next move may depend on whether the recent share price decline has already captured the key risks around Ultragenyx Pharmaceutical, or if the current valuation still builds in expectations that are too optimistic.
Is Ultragenyx Pharmaceutical Getting Expensive on Sales?
P/S is often a useful check for Ultragenyx Pharmaceutical because revenue can be more stable than earnings for companies that are still investing heavily and reporting losses.
Ultragenyx Pharmaceutical currently trades on a P/S multiple of 3.5x. This is below the Biotechs industry average P/S of 11.1x and also below the peer average of 7.9x. However, a more tailored fair P/S ratio that takes into account Ultragenyx Pharmaceutical's business profile and risk level sits lower at 2.6x. That leaves the current share price at a premium to this fair multiple, even if it screens below broad sector benchmarks.
Despite ongoing attention on setrusumab following the recent Mereo BioPharma update, the market is still pricing Ultragenyx Pharmaceutical above what the fair P/S model suggests would be in line with its characteristics. The gap is not extreme, but it does point to investors already assigning a degree of optimism to future revenue delivery at today's price.
On this P/S check, Ultragenyx Pharmaceutical stock screens as overvalued relative to the fair multiple implied by its own fundamentals.
See what the numbers say about this price — find out in our valuation breakdown.
The Ultragenyx Pharmaceutical Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where this Ultragenyx Pharmaceutical valuation puzzle leaves off. They explain which assumptions on Ultragenyx Pharmaceutical's future growth, margins and earnings would need to hold for the stock to be valued significantly above or below the current price. Each Narrative treats fair value as a thesis about the business that you can observe and assess over time. These Narratives are available on Simply Wall St's Community page.
One of the top community narratives on Ultragenyx Pharmaceutical: roughly fairly valued
"Ultragenyx has phenomenal science, but its commercial execution is a cash-incinerating treadmill, and at these multiples, the safety margin for a 2027 BEP inflection is practically non-existent."
Read one of the top narratives on Ultragenyx Pharmaceutical
Do you think there's more to the story for Ultragenyx Pharmaceutical? Head over to our Community to see what others are saying!
The Bottom Line
For Ultragenyx Pharmaceutical, the key takeaway is that the stock screens as mildly overvalued on the current P/S workup, even though broader valuation checks look mixed rather than extreme. The recent weakness in the share price has not yet removed the premium to the tailored fair multiple, which suggests investors are still paying up for the potential of setrusumab and the wider pipeline. The debate from here is whether execution on those programs can match the optimism already embedded in the multiple, or whether expectations need to cool further before the risk and reward feel better balanced.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com